REFERENCES
1. GINA committee. Global Strategy for Asthma Management and Prevention
2022 Update [Internet]. Global Initiative for Asthma. 2022. p. 225.
Available from: http://www.ginasthma.org
2. Van Den Akker-Van Marle ME, Bruil J, Detmar SB. Evaluation of cost of
disease: Assessing the burden to society of asthma in children in the
European Union. Allergy Eur J Allergy Clin Immunol. 2005;60(2):140–9.
3. CIHI. Asthma Hospitalizations Among Children and Youth in Canada:
Trends and Inequalities — Chartbook | CIHI.
https://www.cihi.ca/en/document/asthma-hospitalizations-among-children-
and-youth-in-canada-trends-and-inequalities. 2018.
4. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin
Mol Hepatol. 2014;20(4):327–37.
5. Ferrante G, La Grutta S. The burden of pediatric asthma. Front
Pediatr. 2018;6(June):1–7.
6. Perry R, Braileanu G, Palmer T, Stevens P. The Economic Burden of
Pediatric Asthma in the United States : Literature Review of Current
Evidence. Pharmacoeconomics [Internet]. 2019;37(2):155–67.
7. Ahmed H, Turner S. Severe asthma in children — a review of
definitions , epidemiology , and treatment options in 2019. Pediatr
Pulmonol. 2019;54(6):778–87.
8. Blasco Bravo AJ, Pérez-Yarza EG, Lázaro y de Mercado P, Bonillo
Perales A, Díaz Vazquez CA, Moreno Galdó A. Coste del asma en pediatría
en España : un modelo de evaluación de costes basado en la prevalencia.
An Pediatr (Barc). 2011;74(3):145–53.
9. Chipps BE, Haselkorn T, Rosén K, Mink DR, Trzaskoma BL, Luskin AT.
Asthma Exacerbations and Triggers in Children in TENOR : Impact on
Quality of Life Study. J Allergy Clin Immunol Pract.
2018;6(1):169-176.e2.
10. Cano-Garcinuño A, Bercedo-Sanz A, Mora-Gandarillas I, Callén-Blecua
MT, Castillo-Laita JA, Forns-Serrallonga D, et al. Association between
quality of life in parents and components of asthma control in children.
J Asthma. 2014;51(10):1089–95.
11. Palomares Ó, Sánchez-Ramón S, Dávila I, Prieto L, de Llano LP,
Lleonart M, et al. dIvergEnt: How IgE axis contributes to the continuum
of allergic asthma and anti-IgE therapies. Int J Mol Sci.
2017;18(6):1–14.
12. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al.
Treatment of childhood asthma with anti-immunoglobulin E antibody
(omalizumab). Pediatrics. 2001;108(2):E36.
13. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF, et
al. Omalizumab for the treatment of exacerbations in children with
inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin
Immunol. 2009;124(6):1210–6.
14. Busse W, Morgan W, Gergen P, Mitchell H, Gern J, Liu A, et al.
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city
children. N Engl J Med. 2011;364(11):1005–15.
15. Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, et
al. Add-on omalizumab in children with severe allergic asthma: A 1-year
real life survey. Eur Respir J. 2013;42(5):1224–33.
16. Deschildre A, Marguet C, Langlois C, Pin I, Rittié J-LL, Derelle J,
et al. Real-life long-term omalizumab therapy in children with severe
allergic asthma. Eur Respir J. 2015 Sep;46(3):856–9.
17. Licari A, Castagnoli R, Denicolò C, Rossini L, Seminara M, Testa G,
et al. Omalizumab in Children with Severe Allergic Asthma: The Italian
Real- Life Experience. 2017;36–42.
18. Brodlie M, McKean MC, Moss S, Spencer DA. The oral
corticosteroid-sparing effect of omalizumab in children with severe
asthma. Arch Dis Child. 2012 Jul;97(7):604–9.
19. Szefler SJ, Zeiger RS, Haselkorn T, Mink DR, Kamath T V., Fish JE,
et al. Economic burden of impairment in children with severe or
difficult-to-treat asthma. Ann Allergy, Asthma Immunol.
2011;107(2):110-119.e1.
20. Chen W, Tavakoli H, FitzGerald JM, Subbarao P, Turvey SE,
Sadatsafavi M. Age trends in direct medical costs of pediatric asthma: a
population-based study. Pediatr Allergy Immunol. 2021;
21. Nieto García A, Garriga-Baraut T, Plaza Martín AM, Nieto Cid M,
Torres Borrego J, Del Mar Folqué Giménez M, et al. Omalizumab outcomes
for up to 6 years in pediatric patients with severe persistent allergic
asthma. Pediatr Allergy Immunol. 2021 Jul;32(5):980-991.
22. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P.
The minimally important difference of the Asthma Control Test. J Allergy
Clin Immunol. 2009 Oct;124(4):719-23.e1.
23. Juniper EF, Svensson K, Mörk A-C, Ståhl E. Measurement properties
and interpretation of three shortened versions of the asthma control
questionnaire. Respir Med. 2005 May;99(5):553–8.
24. The Faustino Orgegozo Foundation. ESTUDIOS, TABLAS Y GRÁFICAS DE
CRECIMIENTO [Internet]. Available from:
http://www.fundacionorbegozo.com/product-showcase/tablas/
25. Spanish General Council of Official Associations of Pharmacists
[Internet]. 2022. Available from: https://botplusweb.portalfarma.com
26. Head of State of Spain. Extraordinary measures to reduce the public
deficit - Amended by the Royal Decree-Law 9/2011. [Internet].
BOE-A-2010-8228 - BOE-A-2011-14021. 2010. p. 4–56. Available from:
https://www.boe.es/eli/es/rdl/2010/05/20/8/con
27. Vennera MDC, Sabadell C, Picado C. Duration of the efficacy of
omalizumab after treatment discontinuation in “real life” severe
asthma. Thorax. 2018 Aug; 73(8):782-784.
28. Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, Padilla-Galo
A, Levy A, Álvarez Gutiérrez FJ, et al. Economic Impact and Clinical
Outcomes of Omalizumab Add-On Therapy for Patients with Severe
Persistent Asthma: A Real-World Study. PharmacoEconomics - open. 2019
Sep;3(3):333–42.
29. Martínez-Moragón E, Climent M, Chiner E, Fernández-Aracil C,
Sánchez-Toril F, Lluch-Tortajada I. Effectiveness and pharmacoeconomic
analysis of the treatment of severe asthma with omalizumab in clinical
practice. Farm Hosp. 2019 May;43(3):101–9.
30. Arrobas A, Barbosa MP, Rabiais S, Vandewalle B, Félix J.
Cost-effectiveness of omalizumab in real world uncontrolled allergic
asthma patients. Pulmonology. 2021;27(2):124–33.
31. Levy AN, García A Ruiz AJ, García-Agua Soler N, Sanjuan MVH.
Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a
real-life perspective. J asthma. 2015 Mar;52(2):205–10.
32. Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the
cost/utility of add-on omalizumab in persistent difficult-to-treat
atopic asthma in Italy. J asthma. 2012 Oct;49(8):843–8.
33. Zhou H, Lu Y, Wu B, Che D. Cost-effectiveness of omalizumab for the
treatment of inadequately controlled severe allergic asthma in Chinese
children. J Asthma. 2020 Dec 3 [cited 2018 Dec 27];57(1):87–94.
34. Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, et al.
Cost-effectiveness of omalizumab for the treatment of moderate-to-severe
uncontrolled allergic asthma in the United States. Curr Med Res Opin.
2020 Jan;36(1):23–32.
35. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL.
Cost-effectiveness of omalizumab in adults with severe asthma: results
from the Asthma Policy Model. J Allergy Clin Immunol. 2007
Nov;120(5):1146–52.
36. Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo
S, et al. Omalizumab for Severe Allergic Asthma Treatment in Italy: A
Cost-Effectiveness Analysis from PROXIMA Study. Risk Manag Healthc
Policy. 2020;13:43–53.
37. De Cock E, Miravitlles M, González-Juanatey JR, Azanza-Perea JR.
Threshold value of the cost for life-years gained by adopting health
technologies in Spain: Evidence from a literature review.
Pharmacoeconomics - Spanish Res Artic. 2007;4(3):97–107.